219 related articles for article (PubMed ID: 22809696)
1. Biliary tract carcinomas: from chemotherapy to targeted therapy.
Marino D; Leone F; Cavalloni G; Cagnazzo C; Aglietta M
Crit Rev Oncol Hematol; 2013 Feb; 85(2):136-48. PubMed ID: 22809696
[TBL] [Abstract][Full Text] [Related]
2. Toward personalized treatment of advanced biliary tract cancers.
Geynisman DM; Catenacci DV
Discov Med; 2012 Jul; 14(74):41-57. PubMed ID: 22846202
[TBL] [Abstract][Full Text] [Related]
3. Optimum chemotherapy for the management of advanced biliary tract cancer.
Ghosn M; Kourie HR; El Rassy E; Chebib R; El Karak F; Hanna C; Nasr D
World J Gastroenterol; 2015 Apr; 21(14):4121-5. PubMed ID: 25892861
[TBL] [Abstract][Full Text] [Related]
4. Systemic therapy for biliary tract cancers.
Hezel AF; Zhu AX
Oncologist; 2008 Apr; 13(4):415-23. PubMed ID: 18448556
[TBL] [Abstract][Full Text] [Related]
5. [The development of chemotherapy to unresectable advanced biliary tract cancer].
Arima S; Naruge D; Kasuga A; Kitamura H; Takasu M; Nagashima F; Furuse J
Gan To Kagaku Ryoho; 2012 Oct; 39(10):1490-3. PubMed ID: 23133874
[No Abstract] [Full Text] [Related]
6. Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer.
Hong YS; Lee J; Lee SC; Hwang IG; Choi SH; Heo JS; Park JO; Park YS; Lim HY; Kang WK
Cancer Chemother Pharmacol; 2007 Aug; 60(3):321-8. PubMed ID: 17143602
[TBL] [Abstract][Full Text] [Related]
7. Development of molecularly targeted therapies in biliary tract cancers: reassessing the challenges and opportunities.
Zhu AX; Hezel AF
Hepatology; 2011 Feb; 53(2):695-704. PubMed ID: 21274890
[TBL] [Abstract][Full Text] [Related]
8. [Current aspects of chemotherapy of metastatic pancreatic and biliary tract carcinomas].
Bokemeyer C; Kollmannsberger C; Oettle H; Kanz L
Praxis (Bern 1994); 2000 Sep; 89(39):1545-52. PubMed ID: 11068508
[TBL] [Abstract][Full Text] [Related]
9. Molecular Targets in Biliary Carcinogenesis and Implications for Therapy.
Oyasiji T; Zhang J; Kuvshinoff B; Iyer R; Hochwald SN
Oncologist; 2015 Jul; 20(7):742-51. PubMed ID: 26025932
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors.
Cantore M; Mambrini A; Fiorentini G; Rabbi C; Zamagni D; Caudana R; Pennucci C; Sanguinetti F; Lombardi M; Nicoli N
Cancer; 2005 Apr; 103(7):1402-7. PubMed ID: 15726542
[TBL] [Abstract][Full Text] [Related]
11. Pharmacotherapeutic options for biliary tract cancer: current standard of care and new perspectives.
Filippi R; Lombardi P; Quarà V; Fenocchio E; Aimar G; Milanesio M; Leone F; Aglietta M
Expert Opin Pharmacother; 2019 Dec; 20(17):2121-2137. PubMed ID: 31550186
[No Abstract] [Full Text] [Related]
12. Systemic treatment options for advanced biliary tract carcinoma.
Xie C; McGrath NA; Monge Bonilla C; Fu J
J Gastroenterol; 2020 Oct; 55(10):944-957. PubMed ID: 32748173
[TBL] [Abstract][Full Text] [Related]
13. Gallbladder and biliary tract carcinoma: A comprehensive update, Part 1.
Rajagopalan V; Daines WP; Grossbard ML; Kozuch P
Oncology (Williston Park); 2004 Jun; 18(7):889-96. PubMed ID: 15255172
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas.
Iwasa S; Morizane C; Okusaka T; Ueno H; Ikeda M; Kondo S; Tanaka T; Nakachi K; Mitsunaga S; Kojima Y; Hagihara A; Hiraoka N
Jpn J Clin Oncol; 2010 Apr; 40(4):313-8. PubMed ID: 20047862
[TBL] [Abstract][Full Text] [Related]
15. New developments in systemic therapy for advanced biliary tract cancer.
Morizane C; Ueno M; Ikeda M; Okusaka T; Ishii H; Furuse J
Jpn J Clin Oncol; 2018 Aug; 48(8):703-711. PubMed ID: 29893894
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer.
Furuse J; Okusaka T; Ohkawa S; Nagase M; Funakoshi A; Boku N; Yamao K; Yamaguchi T; Sato T
Cancer Chemother Pharmacol; 2009 Dec; 65(1):113-20. PubMed ID: 19404641
[TBL] [Abstract][Full Text] [Related]
17. Targeted Therapy in Biliary Tract Cancers.
Merla A; Liu KG; Rajdev L
Curr Treat Options Oncol; 2015 Oct; 16(10):48. PubMed ID: 26266637
[TBL] [Abstract][Full Text] [Related]
18. Biliary tract cancers: understudied and poorly understood.
Chan E; Berlin J
J Clin Oncol; 2015 Jun; 33(16):1845-8. PubMed ID: 25918294
[TBL] [Abstract][Full Text] [Related]
19. Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design.
Sicklick JK; Fanta PT; Shimabukuro K; Kurzrock R
Cancer Metastasis Rev; 2016 Jun; 35(2):263-75. PubMed ID: 26857926
[TBL] [Abstract][Full Text] [Related]
20. Emerging Systemic Therapies in Advanced Unresectable Biliary Tract Cancer: Review and Canadian Perspective.
Tam VC; Ramjeesingh R; Burkes R; Yoshida EM; Doucette S; Lim HJ
Curr Oncol; 2022 Sep; 29(10):7072-7085. PubMed ID: 36290832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
